Incidence of mitochondrial toxicity, death and loss to follow-up by initial treatment.

1<p>Primary endpoint: 37 lactic acidosis, 43 hyperlactatemia.</p>2<p>As indicated by clinician report in the medical record.</p

Univariate and multivariate Cox Regression Analysis for time to lactic acidosis or hyperlactatemia.

<p>Multivariate model with 80 events, 1546 subjects with complete data for all variables.</p

Patient characteristics at study entry by treatment arm, limited to women with BMI≥25 kg/m².

1<p>T-test for continuous where mean and standard deviation reported, and Wilcoxon rank sum where median and IQR reported.</p

Multivariate Cox Regression Analysis for time to lactic acidosis or hyperlactatemia limited to women with BMI≥25 kg/m2.

<p>Multivariate model with 20 events, 298 subjects with complete data for all variables.</p

Kaplan Meier curves for lactic acidosis/hyperlactatemia-free survival for patients initiated on either stavudine- or zidovudine-containing antiretroviral therapy (p = .006).

<p>Kaplan Meier curves for lactic acidosis/hyperlactatemia-free survival for patients initiated on either stavudine- or zidovudine-containing antiretroviral therapy (p = .006).</p

Patient characteristics at study entry by treatment arm.

1<p>Chi-square test was used for categorical variables, T-test for continuous where mean and standard deviation reported, and Wilcoxon rank sum where median and IQR reported.</p

Criteria for lactic acidosis and hyperlactatemia outcomes¹.

1<p>Based on AACTG criteria <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0018736#pone.0018736-Lonergan1" target="_blank">[19]</a>.</p>2<p>Bicarbonate <20 mmol/L or pH<7.35.</p>3<p>New or otherwise unexplained symptoms of nausea or vomiting, abdominal pain or discomfort, abdominal distention, increased hepatic transaminases, unexplained fatigue, dyspnea, weight loss (≥5%), or muscle weakness.</p